Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 2
1987 1
1990 1
1991 1
1993 1
1994 2
1996 1
2000 5
2003 1
2004 3
2005 5
2006 5
2007 2
2010 1
2016 1
2020 1
2021 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Proteomic analysis in canine leishmaniasis.
Britti D, Gaspari M, Massimini G, Casalinuovo F, Morittu VM, Cuda G. Britti D, et al. Among authors: massimini g. Vet Res Commun. 2010 Jun;34 Suppl 1:S91-6. doi: 10.1007/s11259-010-9410-5. Vet Res Commun. 2010. PMID: 20440645
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.
Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E. Delord JP, et al. Among authors: massimini g. Target Oncol. 2021 Jan;16(1):37-46. doi: 10.1007/s11523-020-00768-0. Target Oncol. 2021. PMID: 33170484 Clinical Trial.
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.
Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP. Lebbé C, et al. Among authors: massimini g. Target Oncol. 2021 Jan;16(1):47-57. doi: 10.1007/s11523-020-00767-1. Target Oncol. 2021. PMID: 33211315 Clinical Trial.
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival.
Lazar V, Magidi S, Girard N, Savignoni A, Martini JF, Massimini G, Bresson C, Berger R, Onn A, Raynaud J, Wunder F, Berindan-Neagoe I, Sekacheva M, Braña I, Tabernero J, Felip E, Porgador A, Kleinman C, Batist G, Solomon B, Tsimberidou AM, Soria JC, Rubin E, Kurzrock R, Schilsky RL. Lazar V, et al. Among authors: massimini g. NPJ Precis Oncol. 2021 Apr 28;5(1):33. doi: 10.1038/s41698-021-00171-6. NPJ Precis Oncol. 2021. PMID: 33911192 Free PMC article.
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.
Lebbé C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dréno B. Lebbé C, et al. Among authors: massimini g. Cancers (Basel). 2020 Jun 29;12(7):1727. doi: 10.3390/cancers12071727. Cancers (Basel). 2020. PMID: 32610581 Free PMC article.
Exemestane improves survival compared with megoestrol acetate in postmenopausal patients with advanced breast cancer who have failed on tamoxifen. results Of a double-blind randomised phase III trial.
Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J, Fowst C, Polli A, Di Salle E, Massimini G, Piscitelli G. Kaufmann M, et al. Among authors: massimini g. Eur J Cancer. 2000 Sep;36 Suppl 4:S86-7. doi: 10.1016/s0959-8049(00)00240-9. Eur J Cancer. 2000. PMID: 11056333 Clinical Trial.
33 results